Clinical Cancer Research CR Balducci Frontiers in Basic Cancer Research
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kamai, T.
Right arrow Articles by Oshima, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kamai, T.
Right arrow Articles by Oshima, H.
Clinical Cancer Research Vol. 9, 2632-2641, July 2003
© 2003 American Association for Cancer Research


Molecular Oncology, Markers, Clinical Correlates

Significant Association of Rho/ROCK Pathway with Invasion and Metastasis of Bladder Cancer1

Takao Kamai2, Toshihiko Tsujii, Kyoko Arai, Kentaro Takagi, Hidekazu Asami, Yuji Ito and Hiroyuki Oshima

Department of Urology, Dokkyo University School of Medicine, Tochigi 321-0293 [T. K., T. T., K. A.]; Departments of Urology [T. K., K. T.] and Pathology [H. A., Y. I.], Tokyo Metropolitan Tama Geriatric Hospital, Tokyo; and Department of Urology, Tokyo Medical and Dental University School of Medicine, Tokyo [H. O.], Japan

Purpose: The small GTP-binding protein Rho and its best-characterized downstream effector Rho-associated serine-threonine protein kinase, ROCK, participate in actin cytoskeleton organization, and are linked to pathogenesis and progression of several human tumors. We investigated the roles of Rho and ROCK in bladder cancer.

Experimental Design: Using Western blotting, we quantitated Rho and ROCK protein expression in paired tumor and nontumor surgical samples from 107 consecutive Japanese patients with bladder cancer.

Results: RhoA, RhoC, and ROCK were more abundant in tumors and metastatic lymph nodes than in nontumor bladder and uninvolved lymph nodes (P < 0.0001). Amounts of RhoA and RhoC protein, and ROCK protein expression correlated positively with one another (P < 0.0001). High RhoA, RhoC, and ROCK expression were related to poor tumor differentiation (P < 0.05, P < 0.01, and P < 0.01, respectively), muscle invasion (P < 0.001), and lymph node metastasis (P < 0.05). Kaplan-Meier plots linked high RhoA, RhoC, and ROCK protein expression to shortened disease-free and overall survival (P < 0.0001). By univariate analysis, high RhoA, RhoC, and ROCK protein expression predicted shortened disease-free and overall survival (P < 0.0001). By multivariate analysis, only RhoC was independently influenced in disease-free survival (P < 0.05), and RhoA and RhoC in overall survival (P < 0.001). In contrast, RhoB expression was inversely related to the grade and stage (P < 0.05), and its higher expression is associated with better overall survival (P < 0.05). In superficial tumors (Ta or T1; 63 patients), RhoA, RhoC, and ROCK were unrelated with recurrence-free survival. Overall survival in tumors invading muscle (T2 to T4; 44 patients) was significantly influenced by RhoA, RhoC, and ROCK in a Kaplan-Meier analysis (P < 0.0001, P < 0.0001, and P < 0.01, respectively). Whereas RhoA, RhoC, and ROCK independently predicted shortened overall survival in patients with invasive tumor by univariate analysis (P < 0.0001, P < 0.0001, and P < 0.01, respectively), only RhoC did so by multivariate analysis (P < 0.05).

Conclusion: Rho/ROCK pathway apparently involved in occurrence and progression of bladder cancer may be valuable prognostic markers.




This article has been cited by other articles:


Home page
BioinformaticsHome page
H. Li, C. Y. Ung, X. H. Ma, B. W. Li, B. C. Low, Z. W. Cao, and Y. Z. Chen
Simulation of crosstalk between small GTPase RhoA and EGFR-ERK signaling pathway via MEKK1
Bioinformatics, February 1, 2009; 25(3): 358 - 364.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
X. Zhao, L. Lu, N. Pokhriyal, H. Ma, L. Duan, S. Lin, N. Jafari, H. Band, and V. Band
Overexpression of RhoA Induces Preneoplastic Transformation of Primary Mammary Epithelial Cells
Cancer Res., January 15, 2009; 69(2): 483 - 491.
[Abstract] [Full Text] [PDF]


Home page
Endocr Relat CancerHome page
C. Laezza, S. Pisanti, A. M. Malfitano, and M. Bifulco
The anandamide analog, Met-F-AEA, controls human breast cancer cell migration via the RHOA/RHO kinase signaling pathway
Endocr. Relat. Cancer, December 1, 2008; 15(4): 965 - 974.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
W. Wang, F. Wu, F. Fang, Y. Tao, and L. Yang
Inhibition of Invasion and Metastasis of Hepatocellular Carcinoma Cells via Targeting RhoC In vitro and In vivo
Clin. Cancer Res., November 1, 2008; 14(21): 6804 - 6812.
[Abstract] [Full Text] [PDF]


Home page
IOVSHome page
J. Chen, E. Guerriero, K. Lathrop, and N. SundarRaj
Rho/ROCK Signaling in Regulation of Corneal Epithelial Cell Cycle Progression
Invest. Ophthalmol. Vis. Sci., January 1, 2008; 49(1): 175 - 183.
[Abstract] [Full Text] [PDF]


Home page
Ann. Surg. Oncol.Home page
A. Faried, L. S. Faried, N. Usman, H. Kato, and H. Kuwano
Clinical and Prognostic Significance of RhoA and RhoC Gene Expression in Esophageal Squamous Cell Carcinoma
Ann. Surg. Oncol., December 1, 2007; 14(12): 3593 - 3601.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
H. Lu, K. L. Knutson, E. Gad, and M. L. Disis
The Tumor Antigen Repertoire Identified in Tumor-Bearing Neu Transgenic Mice Predicts Human Tumor Antigens
Cancer Res., October 1, 2006; 66(19): 9754 - 9761.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
D. R. Croft and M. F. Olson
The Rho GTPase Effector ROCK Regulates Cyclin A, Cyclin D1, and p27Kip1 Levels by Distinct Mechanisms
Mol. Cell. Biol., June 15, 2006; 26(12): 4612 - 4627.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
T. H.-Y. Leung, Y.-P. Ching, J. W. P. Yam, C.-M. Wong, T.-O. Yau, D.-Y. Jin, and I. O.-L. Ng
Deleted in liver cancer 2 (DLC2) suppresses cell transformation by means of inhibition of RhoA activity
PNAS, October 18, 2005; 102(42): 15207 - 15212.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
C.-M. Wong, J. W.-P. Yam, Y.-P. Ching, T.-O. Yau, T. H.-Y. Leung, D.-Y. Jin, and I. O.-L. Ng
Rho GTPase-Activating Protein Deleted in Liver Cancer Suppresses Cell Proliferation and Invasion in Hepatocellular Carcinoma
Cancer Res., October 1, 2005; 65(19): 8861 - 8868.
[Abstract] [Full Text] [PDF]


Home page
Endocr Relat CancerHome page
W-B Zhong, Y-C Liang, C-Y Wang, T-C Chang, and W-S Lee
Lovastatin suppresses invasiveness of anaplastic thyroid cancer cells by inhibiting Rho geranylgeranylation and RhoA/ROCK signaling
Endocr. Relat. Cancer, September 1, 2005; 12(3): 615 - 629.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
B. Titus, H. F. Frierson Jr., M. Conaway, K. Ching, T. Guise, J. Chirgwin, G. Hampton, and D. Theodorescu
Endothelin Axis Is a Target of the Lung Metastasis Suppressor Gene RhoGDI2
Cancer Res., August 15, 2005; 65(16): 7320 - 7327.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
A. Ramirez de Molina, D. Gallego-Ortega, J. Sarmentero, M. Banez-Coronel, Y. Martin-Cantalejo, and J. C. Lacal
Choline Kinase Is a Novel Oncogene that Potentiates RhoA-Induced Carcinogenesis
Cancer Res., July 1, 2005; 65(13): 5647 - 5653.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
J.-Y. Lang, H. Chen, J. Zhou, Y.-X. Zhang, X.-W. Zhang, M.-H. Li, L.-P. Lin, J.-S. Zhang, M. P. Waalkes, and J. Ding
Antimetastatic Effect of Salvicine on Human Breast Cancer MDA-MB-435 Orthotopic Xenograft Is Closely Related to Rho-Dependent Pathway
Clin. Cancer Res., May 1, 2005; 11(9): 3455 - 3464.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
H. Zhou and R. H. Kramer
Integrin Engagement Differentially Modulates Epithelial Cell Motility by RhoA/ROCK and PAK1
J. Biol. Chem., March 18, 2005; 280(11): 10624 - 10635.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
D. R. Croft, E. Sahai, G. Mavria, S. Li, J. Tsai, W. M. F. Lee, C. J. Marshall, and M. F. Olson
Conditional ROCK Activation In vivo Induces Tumor Cell Dissemination and Angiogenesis
Cancer Res., December 15, 2004; 64(24): 8994 - 9001.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
W. Wang, S. Goswami, K. Lapidus, A. L. Wells, J. B. Wyckoff, E. Sahai, R. H. Singer, J. E. Segall, and J. S. Condeelis
Identification and Testing of a Gene Expression Signature of Invasive Carcinoma Cells within Primary Mammary Tumors
Cancer Res., December 1, 2004; 64(23): 8585 - 8594.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
K. J. Simpson, A. S. Dugan, and A. M. Mercurio
Functional Analysis of the Contribution of RhoA and RhoC GTPases to Invasive Breast Carcinoma
Cancer Res., December 1, 2004; 64(23): 8694 - 8701.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
N. Liu, F. Bi, Y. Pan, L. Sun, Y. Xue, Y. Shi, X. Yao, Y. Zheng, and D. Fan
Reversal of the Malignant Phenotype of Gastric Cancer Cells by Inhibition of RhoA Expression and Activity
Clin. Cancer Res., September 15, 2004; 10(18): 6239 - 6247.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
L. G. Strauss, A. Dimitrakopoulou-Strauss, D. Koczan, L. Bernd, U. Haberkorn, V. Ewerbeck, and H.-J. Thiesen
18F-FDG Kinetics and Gene Expression in Giant Cell Tumors
J. Nucl. Med., September 1, 2004; 45(9): 1528 - 1535.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
J. M. Vasiliev, T. Omelchenko, I. M. Gelfand, H. H. Feder, and E. M. Bonder
From the Cover: Rho overexpression leads to mitosis-associated detachment of cells from epithelial sheets: A link to the mechanism of cancer dissemination
PNAS, August 24, 2004; 101(34): 12526 - 12530.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
T. Kamai, T. Yamanishi, H. Shirataki, K. Takagi, H. Asami, Y. Ito, and K.-I. Yoshida
Overexpression of RhoA, Rac1, and Cdc42 GTPases Is Associated with Progression in Testicular Cancer
Clin. Cancer Res., July 15, 2004; 10(14): 4799 - 4805.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
L. M. McHardy, R. Sinotte, A. Troussard, C. Sheldon, J. Church, D. E. Williams, R. J. Andersen, S. Dedhar, M. Roberge, and C. D. Roskelley
The Tumor Invasion Inhibitor Dihydromotuporamine C Activates RHO, Remodels Stress Fibers and Focal Adhesions, and Stimulates Sodium-Proton Exchange
Cancer Res., February 15, 2004; 64(4): 1468 - 1474.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
T. Ikoma, T. Takahashi, S. Nagano, Y.-M. Li, Y. Ohno, K. Ando, T. Fujiwara, H. Fujiwara, and K.-i. Kosai
A Definitive Role of RhoC in Metastasis of Orthotopic Lung Cancer in Mice
Clin. Cancer Res., February 1, 2004; 10(3): 1192 - 1200.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2003 by the American Association for Cancer Research.